Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: Oncology
Clinical Trials: Chronic Lymphocytic Leukemia
A listing of clinical trials currently looking for volunteers to enroll in Chronic Lymphocytic Leukemia studies. Click on the closest city to find more detailed information on a research study in your area.
Alabama
Birmingham : University of Alabama at Birmingham
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Birmingham : Uab Comprehensive Cancer Center
First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers
Huntsville : Clearview Cancer Institute
A Randomized, Double-Blind and Placebo-Controlled Study of GS-1101 in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)
Huntsville : Clearview Cancer Institute
An Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study
Huntsville : Clearview Cancer Institute
Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia
View More »
Huntsville : Clearview Cancer Institute
Study to Investigate CAL-101 in Combination With Chemotherapeutic Agents and CD20 mAb in Patients With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia
Muscle Shoals : Northwest Alabama Cancer Center, PC
Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.
Arizona
Scottsdale : Mayo Clinic Arizona - Cancer Clinical Research Unit Updated
A Study of CDX-1127 in Patients With Select Solid Tumor Types or Hematologic Cancers
Tucson : University of Arizona (SPORE)
Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia
California
Duarte : City of Hope
A Phase II Multicenter Trial of Myeloablative Double Unit Umbilical Cord Blood Transplantation (UCBT) in Adults with Hematologic Malignancy
Duarte : City of Hope Updated
Acquisition of Peripheral Blood and/or Bone Marrow Aspirate from Patients with Chronic Lymphocytic Leukemia for Method Development of
Aptamers Based Delivery Method of RNAi
Duarte : City of Hope Updated
An Open Label, Multicenter, Phase 1b Trial of GA101 (RO5072759) in Combination with Chemotherapy in Patients with Previously Untreated Chronic Lymphocytic Leukemia
Duarte : City of Hope
SWOG 9007: Cytogenetic Studies In Leukemia Patients
View More »
Burbank : East Valley Hematology and Oncology Medical Group
Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.
Concord : Bay Area Cancer Research Group
Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.
Fountain Valley : Lalita Pandit, MD, Inc.
Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.
Fountain Valley : Pacific Coast Hematology/Oncology Medical Group, Inc.
Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.
Fountain Valley : Robert A. Moss, M.D. FACP, Inc.
Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.
La Jolla : Site Reference ID/Investigator# 48325
A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphoma
La Jolla :
A Study of GA101 (RO5072759) in Combination With Chemotherapy in Patients With Previously Untreated Chronic Lymphocytic Leukemia (GALTON)
La Jolla : Scripps Cancer Center
A Study Using Two Oral Chemotherapy Agents for Chronic Lymphocytic Leukemia
La Jolla : University of California, San Diego
Multi-center Trial of Revlimid® and Rituximab for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
La Jolla : University of California San Diego
Multi-center Trial of Revlimid® and Rituximab, for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)
La Jolla : Moores UCSD Cancer Center Updated
Revlimid® as Consolidation Treatment Chronic Lymphocytic Leukemia
La Jolla : UCSD Medical Center
Sorafenib for the Treatment of Chronic Lymphocytic Leukemia (CLL)
Los Angeles :
A Study of GA101 (RO5072759) in Combination With Chemotherapy in Patients With Previously Untreated Chronic Lymphocytic Leukemia (GALTON)
Los Angeles : UCLA
An Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study
Los Angeles : Metropolitan Hematology Oncology Medical Group
Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.
Los Angeles : Ucla-Division Of Hematology/Oncology
First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers
Los Angeles : Usc - Norris Comprehensive Cancer Center And Hospital
First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers
Los Angeles : UCLA
Study to Investigate CAL-101 in Combination With Chemotherapeutic Agents and CD20 mAb in Patients With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia
Oceanside : North County Oncology
Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.
Oxnard : Ventura County Hematology Oncology Specialists
Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.
Palo Alto : Stanford Cancer Center
An Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study
Palo Alto : Stanford Cancer Center
Study to Investigate CAL-101 in Combination With Chemotherapeutic Agents and CD20 mAb in Patients With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia
Rancho Mirage : Cancer and Blood Institute Medical Group
Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.
San Diego : Moores UCSD Cancer Center
Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia
Stanford : Investigational Site
A Study of the Safety and Pharmacokinetics of Escalating Doses of DCDT2980S in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia And DCDT2980S in Combination With Rituximab in Patients With Relapsed or Refractory B-Cell Non Hodgkin's Lymphoma
Stockton : St. Teresa Comprehensive Cancer Center
Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.
Vista : Medical Group of North County
Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.
Colorado
Aurora : Investigational Site Number 840004
Study Combining SAR245409 With Bendamustine and/or Rituximab in Subjects With Indolent Lymphoma, Mantle Cell Lymphoma & Chronic Lymphocytic Leukemia
Colorado Springs : The Oncology Clinic, PC
Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.
Denver : Investigational Site
A Study of the Safety and Pharmacokinetics of Escalating Doses of DCDT2980S in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia And DCDT2980S in Combination With Rituximab in Patients With Relapsed or Refractory B-Cell Non Hodgkin's Lymphoma
Denver : Rocky Mountain Cancer Centers - Denver
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Denver : Mile High Oncology
Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.
Connecticut
New Haven : Yale Cancer Center
Maintenance Therapy: Lenalidomide Following Bendamustine and Rituximab Induction Therapy for Chronic Lymphocytic Leukemia
Florida
Atlantis : Medical Specialists of the Palm Beaches
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Boynton Beach : Collaborative Research Group
A Extension Study of GS-1101 for Patients With Chronic Lymphocytic Leukemia Who Participated in GS-US-312-0116
Boynton Beach : Collaborative Research Group LLC
A Randomized, Double-Blind and Placebo-Controlled Study of GS-1101 in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)
Boynton Beach : University Cancer Institute
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Boynton Beach : Thomas Niederman, MD
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
View More »
Boynton Beach : Palm Beach Institute of Hematology and Oncology
Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.
Fort Myers : Florida Cancer Specialists
Fludarabine, Rituximab, and Lenalidomide in Minimally Treated/Untreated Patients With CLL
Jacksonville : Integrated Community Oncology Network
Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.
Jacksonville : Mayo Clinic
Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia
Kissimmee : Osceola Cancer Center
Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.
New Port Richey : Pasco Hernando Oncology Associates (Kumar)
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
New Port Richey : Pasco Hernando Oncology Associates, PA
Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.
New Port Richey : Pasco Pinellas Cancer Center
Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.
Ocala : Ocala Oncology Center
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Orlando : Florida Hospital Cancer Institute
Fludarabine, Rituximab, and Lenalidomide in Minimally Treated/Untreated Patients With CLL
Tampa :
A Study of GA101 (RO5072759) in Combination With Chemotherapy in Patients With Previously Untreated Chronic Lymphocytic Leukemia (GALTON)
Tampa : H. Lee Moffitt Cancer Center and Research Institute
Phase II Ofatumumab/Methylprednisolone Followed by Ofatumumab/Lenalidomide for Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Georgia
Albany : Phoebe Putney Memorial Hospital
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Atlanta : Emory University Winship Cancer Institute
A Phase I Trial Using Cyclophosphamide, Rituximab and Revlimid (CR2) for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Small Lymphocytic Lymphoma (SLL)
Atlanta :
A Study of GA101 (RO5072759) in Combination With Chemotherapy in Patients With Previously Untreated Chronic Lymphocytic Leukemia (GALTON)
Atlanta : Georgia Cancer Specialists
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Atlanta : Peachtree Hematology-Oncology Consultants
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
View More »
Augusta : Augusta Oncology Associates, PC
Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.
Augusta : Investigational Site Number 840006
Study Combining SAR245409 With Bendamustine and/or Rituximab in Subjects With Indolent Lymphoma, Mantle Cell Lymphoma & Chronic Lymphocytic Leukemia
Dublin : US Oncology - Dublin Hematology & Oncology
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Griffin : Spalding Oncology Services
Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.
Marietta :
A Study of GA101 (RO5072759) in Combination With Chemotherapy in Patients With Previously Untreated Chronic Lymphocytic Leukemia (GALTON)
Hawaii
Honolulu : Straub Clinic and Hospital
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Idaho
Boise : St Luke's Mountain States Tumor Institute
Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.
Illinois
Arlington Heights : US Oncology - Cancer Care & Hematology Specialists of Chicagoland - Arlington
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Chicago : Rush University Medical Center
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Chicago : John H. Stroger, Jr., Hospital of Cook County
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Chicago : Northwestern University
Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia
Gurnee : Oncology Hematology Assoc. of Northern Illinois
Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.
View More »
Harvey : Ingalls Cancer Research Center
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Lombard : Elmhurst Memorial Hospital
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Niles : Oncology Specialists, S.C.
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Niles : US Oncology - Cancer Care & Hematology Specialists of Chicagoland - Niles
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Peoria : Illinois Cancer Care
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Skokie : Orchard Research
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Urbana : Carle Cancer Center
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Winfield : US Oncology - Cancer Care & Hematology Specialists of Chicagoland - Winfield
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Indiana
Beech Grove : St. Francis Cancer Research
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Goshen : Center for Cancer Care @ Goshen Health Systems
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Indianapolis : Indiana University Simon Cancer Center IU Simon Cancer Center Clinical Research Office, RT 380
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Indianapolis : Indiana University Cancer Center Clinical Research Office
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Indianapolis : Indiana Oncology Hematology Consultants
Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.
View More »
Lafayette : Arnett Cancer Care
Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.
Lafayette : Horizon Oncology Center
Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia
Mishawaka : Cancer Care Partners, LLC
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
New Albany : Cancer Care Center, Inc.
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
New Albany : Cancer Care Center
Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.
Iowa
Ames : McFarland Clinic
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Bettendorf : Hematology Oncology Associates of the Quad Cities
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Cedar Rapids : Iowa Blood and Cancer Care of PCI
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Waterloo : Covenant Clinic
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Kansas
Wichita : Cancer Center of Kansas, PA
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Kentucky
Hazard : Kentucky Cancer Clinic
Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.
Louisiana
Baton Rouge : Mary Bird Perkins Cancer Center
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Maryland
Baltimore : Auerbach Hematology Oncology Associates, Inc.
Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.
Baltimore : Greater Baltimore Medical Center
Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.
Baltimore : Chesapeake Oncology Hematology Associates
Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.
Baltimore : B. Douglas Smith, M.D.
First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers
Bethesda : Center for Cancer & Blood Disorders, PC
An Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study
View More »
Bethesda : Center for Cancer and Blood Disorders
Fludarabine, Rituximab, and Lenalidomide in Minimally Treated/Untreated Patients With CLL
Bethesda : National Capital Clinical Research Consortium
Fludarabine, Rituximab, and Lenalidomide in Minimally Treated/Untreated Patients With CLL
Bethesda : Center for Cancer and Blood Disorders
Study to Investigate CAL-101 in Combination With Chemotherapeutic Agents and CD20 mAb in Patients With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia
Boston :
A Study of GA101 (RO5072759) in Combination With Chemotherapy in Patients With Previously Untreated Chronic Lymphocytic Leukemia (GALTON)
Cumberland : Western Maryland Health System, Inc.
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Westminster : Alliance Hematology Oncology, PA
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Massachusetts
Boston : Site Reference ID/Investigator# 48324
A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphoma
Boston :
A Study of GA101 (RO5072759) in Combination With Chemotherapy in Patients With Previously Untreated Chronic Lymphocytic Leukemia (GALTON)
Boston : Dana-Farber Cancer Institute
An Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study
Boston : Dana-Farber Cancer Institute
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Boston : Massachusetts General Hospital
Dasatinib With Fludarabine and Rituximab in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
View More »
Boston : Dana-Farber Cancer Institute
Dasatinib With Fludarabine and Rituximab in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Boston : Dana Farber Cancer Institute
Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia
Boston : Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute
Multi-center Trial of Revlimid® and Rituximab, for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)
Hyannis : Capecod Hospital / Davenport Mugar Cancer Center
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Worcester : Fallon Clinic
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Michigan
Ann Arbor : Investigational Site
A Study of the Safety and Pharmacokinetics of Escalating Doses of DCDT2980S in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia And DCDT2980S in Combination With Rituximab in Patients With Relapsed or Refractory B-Cell Non Hodgkin's Lymphoma
Ann Arbor : University of Michigan,Department of Internal Med. Hematology- Oncology
Stem Cell Transplantation To Treat High Risk Lymphoid Diseases With Reduced Toxicity Myeloablative Conditioning Regimen
Flint : Michigan State University / McLaren Regional Medical Center
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Flint : Genesee Cancer & Blood Disease Treatment Center, PC
Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.
Freesoil : West Michigan Regional Cancer & Blood Center
Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.
View More »
Grand Rapids : Cancer and Hematology Centers of Western Michigan
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Grand Rapids : Spectrum Health Hospitals
Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.
Kalamazoo : West Michigan Cancer Center
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Minnesota
Duluth : Duluth Clinic Cancer Center
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Minneapolis : Minnesota Oncology Hematology P.A.
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Rochester : Mayo Clinic Updated
A Study of CDX-1127 in Patients With Select Solid Tumor Types or Hematologic Cancers
St. Louis Park : Park Nicollet Institute - Louisiana Ave.
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
St. Louis Park : Park Nicollet Institute Metro - MN CCOP
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Mississippi
Missouri
Branson : Branson Oncology Clinic
Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.
Columbia : US Oncology - Missouri Cancer Associates
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Jefferson City : Capitol Comprehensive Cancer Care Clinic
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Springfield : St. John's Medical Research Institute
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
St. Joseph : St. Joseph Oncology, Inc.
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
View More »
St. Louis : Washington University School of Medicine
An Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study
St. Louis : Hematology Oncology Consultants, Inc.
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
St. Louis : St. Louis Hematology Oncology Specialists, Inc.
Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.
St. Louis : Washington University School of Medicine
Study to Investigate CAL-101 in Combination With Chemotherapeutic Agents and CD20 mAb in Patients With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia
Montana
Missoula : Montana Cancer Institute Foundation
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Nebraska
Lincoln : Nebraska Hematology Oncology, PC
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Lincoln : Southeast Nebraska Hematology & Oncology Consultants, PC
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Nevada
Carson City : Sierra Nevada Oncology Care
Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.
Las Vegas : Southern Nevada Cancer Research Foundation
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Las Vegas : Nevada Cancer Center
Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.
Reno : VA Sierra Nevada Healthcare System
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
New Jersey
Cherry Hill : The Center for Cancer and Hematologic Disease
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Cherry Hill : The Center for Cancer and Hematologic Disease
Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.
Elizabeth : Ellioth Fishkin, MD
Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.
Englewood : Drs. Forte, Schleider, Attas & Condemi, PA
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Hackensack : Hackensack University Medical Center
A Randomized, Double-Blind and Placebo-Controlled Study of GS-1101 in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)
View More »
Hackensack : Investigational Site
A Study of the Safety and Pharmacokinetics of Escalating Doses of DCDT2980S in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia And DCDT2980S in Combination With Rituximab in Patients With Relapsed or Refractory B-Cell Non Hodgkin's Lymphoma
Hackensack : Research Site
AMG 319 Lymphoid Malignancy FIH
Morristown : Charles Farber, MD
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Morristown : Hematology Oncology of Northern New Jersey
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Somerville : Steeplechase Cancer Center
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
New York
New Hyde Park : Biomedical Research Alliance of New York
Non-Hodgkin’s Lymphoma or Chronic Lymphocytic Leukemia
View More »
Albany : Samuel S Stratton VAMC
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Bay Shore : Hematology Oncology Associates of Western Suffolk
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Bronx : Bronx River Medical Associates
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Bronx : Eastchester Center for Cancer Care
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Bronxville : Eduardo Saponara, MD
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Buffalo : Jonah Cancer Care Center & ECMC
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Johnson City : Broome Oncology
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Mount Kisco : Westchester Hematology Oncology Associates
Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.
New Hyde Park : Long Island Jewish Medical Center
A Randomized, Double-Blind and Placebo-Controlled Study of GS-1101 in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)
New Hyde Park : Long Island Jewish Medical Center
Multi-center Trial of Revlimid® and Rituximab, for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)
New Hyde Park : Long Island Jewish Medical Center
Study to Investigate CAL-101 in Combination With Chemotherapeutic Agents and CD20 mAb in Patients With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia
New York : Weill Medical College of Cornell
An Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study
New York : Mount Sinai School of Medicine & Mount Sinai Graduate School of biological Sciences
Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia
New York : Memorial Sloan-Kettering Cancer Center
Lenalidomide in Patients With Chronic Lymphocytic Leukemia Older Than 65 Years of Age
New York : Mount Sinai Medical Center
Phase I Study of ON 01910.Na in Refractory Leukemia or Myelodysplastic Syndrome (MDS)
New York : Weill Cornell Medical College
Phase I Trial of Anti-CD74 (hLL1) Antibody Therapy in B Cell Malignancies
New York : Weill Medical College of Cornell
Study to Investigate CAL-101 in Combination With Chemotherapeutic Agents and CD20 mAb in Patients With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia
Rochester :
A Study of GA101 (RO5072759) in Combination With Chemotherapy in Patients With Previously Untreated Chronic Lymphocytic Leukemia (GALTON)
Rochester : University of Rochester Medical Center
Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia
Syracuse : SUNY Upstate Medical University - Adult Program
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
North Carolina
Cary : US Oncology - Cancer Centers of North Carolina - Cary
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Durham : Research Site
AMG 319 Lymphoid Malignancy FIH
Raleigh : US Oncology - Cancer Centers of North Carolina - Falls
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Raleigh : US Oncology - Cancer Centers of North Carolina - Macon
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
North Dakota
Bismarck : Legacy Pharma Research
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Bismarck : Mid Dakota Clinic/Odyssey Research
Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.
Fargo : Roger Maris Cancer Center
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Ohio
Akron : Summa Health System - Cancer Research Office
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Akron : Summa Health System Hospitals
Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.
Canton : Gabrail Cancer Center Research
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Canton : Nashat Y. Gabrail, MD, Inc.
Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.
Cleveland : University Hospitals Case Medical Center
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
View More »
Cleveland : Cleveland Clinic
Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia
Columbus : Mid Ohio Oncology / Hematology, Inc.
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Elyria : Hematology Oncology Center, Inc.
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Oregon
Eugene : Willamette Valley Cancer and Research / USOR
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Eugene : US Oncology - Willamette Valley Cancer Institute - Eugene
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Portland : US Oncology - Northwest Cancer Specialists, PC - Portland - Barnes
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Portland : US Oncology - Northwest Cancer Specialists, PC - Portland - Broadway
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Portland : US Oncology - Northwest Cancer Specialists, PC - Portland - Hoyt
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
View More »
Springfield : US Oncology - Willamette Valley Cancer Institute - Springfield
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Springfield : US Oncology Research: Willamette Valley Cancer Institute and Research Center
Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia
Springfield : Willamette Valley Cancer Institute and Research Center
Study to Investigate CAL-101 in Combination With Chemotherapeutic Agents and CD20 mAb in Patients With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia
Tualatin : US Oncology - Northwest Cancer Specialists, PC - Tualatin
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Tulatin : Northwest Cancer Specialists, P.C.
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Pennsylvania
Bethlehem : Oncology Hematology of Lehigh Valley
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Drexel Hill : Consultants in Medical Oncology and Hematology, PC
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Gettysburg : Gettysburg Cancer Center
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Harrisburg : Andrews and Patel Associates
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Kingston : US Oncology - Medical Oncology Associates (Nahar)
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
View More »
Lancaster : Lancaster Cancer Center
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Norristown : Luitpold Pharmaceuticals, Inc.
Bioequivalence Trial of Luitpold Azacitidine Versus Vidaza® in Patients With Myelodysplastic Syndrome, Myelofibrosis, Chronic Myeloid Leukemia or Chronic Lymphocytic Leukemia
Philadelphia : Thomas Jefferson University
Combination of Pentostatin, Bendamustine and Ofatumumab for Treatment of Chronic Lymphocytic Leukemia and Lymphoma
Reading : Berks Hematology Oncology Associates
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Rhode Island
Cranston : Hematology & Oncology Associates of Rhode Island
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Cranston : Sambandam and Joseph Associates, Inc
Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.
South Carolina
Charleston : Charleston Hematology Oncology Associates, PA
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Charleston : Charleston Hematology Oncology, PA
Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.
Charleston : Investigational Site Number 840002
Study Combining SAR245409 With Bendamustine and/or Rituximab in Subjects With Indolent Lymphoma, Mantle Cell Lymphoma & Chronic Lymphocytic Leukemia
Charleston : Medical University of South Carolina
Trial of Intracycle Sequential Ofatumumab and Lenalidomide for the Treatment of Chronic Lymphocytic Leukemia in Patients Previously Exposed to Rituximab
Columbia : South Carolina Oncololgy Associates, PA
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
View More »
Columbia : South Carolina Oncology Associates
Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.
Columbia : South Carolina Oncology Associates, PA
Fludarabine, Rituximab, and Lenalidomide in Minimally Treated/Untreated Patients With CLL
Easley : US Oncology - Cancer Centers of the Carolinas - Easley
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Greenville : Saint Francis Hospital
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Greenville : US Oncology - Cancer Centers of the Carlinas - Eastside
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Greenville : US Oncology - Cancer Centers of the Carolinas - Butternut
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Greenville : US Oncology - Cancer Centers of the Carolinas - West Faris
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Greenville : Greenville Hospital System
Trial of Intracycle Sequential Ofatumumab and Lenalidomide for the Treatment of Chronic Lymphocytic Leukemia in Patients Previously Exposed to Rituximab
Seneca : US Oncology - Cancer Centers of the Carolinas - Seneca
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Spartanburg : US Oncology - Cancer Centers of the Carolinas - Spartanburg
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
South Dakota
Sioux Falls : Sanford Clinic
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Tennessee
Bartlett : US Oncology - University of Tennessee Cancer Institute - Bartlett
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Collierville : Family Cancer Center, PLLC
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Collierville : The Family Cancer Center
Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.
Germantown : US Oncology - University of Tennessee Cancer Institute - Germantown
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Germantown : C. Michael Jones, MD, PC
Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.
View More »
Memphis : US Oncology - University of Tennessee Cancer Institute - Memphis
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Nashville : Sarah Cannon Research Institute Updated
A Study of CDX-1127 in Patients With Select Solid Tumor Types or Hematologic Cancers
Nashville : Sarah Cannon Research Institute
An Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study
Nashville : SCRI
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Nashville : Tennessee Oncology, PLLC
Fludarabine, Rituximab, and Lenalidomide in Minimally Treated/Untreated Patients With CLL
Nashville : Sarah Cannon Research Institute
Study to Investigate CAL-101 in Combination With Chemotherapeutic Agents and CD20 mAb in Patients With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia
Texas
Abilene : US Oncology - Texas Cancer Center - Abilene (South)
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Amarillo : US Oncology - Texas Oncology, PA - Amarillo
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Amarillo : Texas Oncology
Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-Match
Arlington : US Oncology - Texas Oncology - Arlington South
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Bedford : US Oncology - Texas Oncology, PA - Bedford
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
View More »
Bryan : St. Joseph Regional Cancer Center
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
College Station : Scott & White Clinic
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Corpus Christi : South Texas Institute of Cancer
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Corpus Christi : Coastal Bend Cancer Center
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Dallas : Mary Crowley Cancer Research Centers - Medical City Updated
A Study of CDX-1127 in Patients With Select Solid Tumor Types or Hematologic Cancers
Dallas : Texas Oncology - Medical City Dallas
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Dallas : US Oncology - Texas Oncology, PA - Dallas
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
El Paso : US Oncology - El Paso Cancer Treatment Center
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
El Paso : US Oncology - El Paso Cancer Treatment Center - West
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Fort Worth : Texas Oncology - Fort Worth 12th Avenue
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Fort Worth : US Oncology - Southwest Fort Worth Cancer Center
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Fort Worth : US Oncology - Texas Oncology, PA - Fort Worth
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Fort Worth : JPS Center for Cancer Care
Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.
Grapevine : US Oncology - Texas Oncology - Grapevine
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Houston :
A Study of GA101 (RO5072759) in Combination With Chemotherapy in Patients With Previously Untreated Chronic Lymphocytic Leukemia (GALTON)
Houston : MD Anderson Cancer and Research Center
An Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study
Houston : MD Anderson Cancer Center / University of Texas
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Houston : MD Anderson Cancer Center
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Houston : Oncology Consultants
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Houston : University of Texas MD Anderson Cancer Center
Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia
Houston : The University Of Texas Md Anderson Cancer Center
First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers
Houston : M. D. Anderson Cancer Center at University of Texas
Multi-center Trial of Revlimid® and Rituximab, for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)
Houston : UT MD Anderson Cancer Center
Nonmyeloablative Stem Cell Transplantation for Chronic Lymphocytic Leukemia (CLL)
Houston : UT MD Anderson Cancer Center
Ofatumumab for High-Risk Chronic Lymphocytic Leukemia (CLL)
Houston : University of Texas M.D. Anderson Cancer Center
Study of Hypoxia-Activated Prodrug TH-302 to Treat Advanced Leukemias
Houston : MD Anderson Cancer
Study to Investigate CAL-101 in Combination With Chemotherapeutic Agents and CD20 mAb in Patients With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia
Houston : MD Anderson Cancer Center
TXA127 in Enhancement of Engraftment in Adult Double Cord Blood Transplantation
Kerrville : US Oncology - San Antonio Tumor & Blood Clinic - Kerrville
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Lackland AFB : Wilford Hall Medical Center
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Longview : US Oncology - Longview Cancer Center
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Lubbock : Joe Arrington Cancer Research and Treatment Center
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
McAllen : US Oncology - Texas Oncology - McAllen
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Mesquite : US Oncology - Texas Oncology - Mesquite
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Midland : US Oncology - Allison Cancer Center
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Paris : US Oncology - Texas Oncology - Paris
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Round Rock : Texas Oncology - Central Austin Cancer Center
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
San Antonio : US Oncology - Cancer Care Centers of South Texas
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
San Antonio : US Oncology - San Antonio Tumor & Blood Clinic - M. Oak
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
San Antonio : University of Texas Health Science Center, San Antonio
Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia
Sherman : US Oncology - Texas Oncology - Sherman
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Temple : Scott & White Healthcare Department of Research
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Tyler : ETMC dba Tyler Hematology Oncology
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Tyler : US Oncology - Texas Oncology - Tyler
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Tyler : ETMC dba Blood and Cancer Center - East Texas
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Waco : US Oncology - Texas Oncology Cancer Care and Research Center
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Weslaco : US Oncology - Texas Oncology - Weslaco
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Wichita Falls : US Oncology - Texoma Cancer Center
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Utah
American Fork : Central Utah Clinic
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Logan : Cache Valley Cancer Treatment & Research Clinic, Inc.
Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.
Ogden : Northern Utah Associates
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Virginia
Abingdon : Cancer Outreach Associates, PC
Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.
Arlington : US Oncology - Arlington Fairfax Hematology Oncology
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Charlottesville : University of Virginia Health System Updated
A Study of CDX-1127 in Patients With Select Solid Tumor Types or Hematologic Cancers
Christianburg : Oncology and Hematology Assoc of SW VA DBA Blue Ridge Cancer Care
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Christiansburg : US Oncology - Onc and Hem Assoc of Southwest VA, Inc - Christiansburg
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
View More »
Fairfax : US Oncology - Fairfax Northern VA Hem-Onc PC
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Gainesville : US Oncology - Fairfax - Northern Virginia Hematology-Oncology, PC - Gainesville
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Leesburg : US Oncology - Fairfax - Northern Virginia Hem-Onc, PC - Leesburg
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Low Moor : US Oncology - Onc and Hem Assoc of Southwest VA, Inc - Low Moor
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Richlands : Virginia Oncology Care, PC
Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.
Roanoke : US Oncology - Onc and Hem Assoc of Southwest VA, Inc - Roanoke
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Salem : US Oncology - Onc and Hem Assoc of Southwest VA, Inc - Salem
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Winchester : US Oncology - Shenandoah Oncology - Winchester
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Woodbridge : US Oncology - Fairfax - Northern Virginia Hem-Onc, PC - Woodbridge
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Wytheville : US Oncology - Onc and Hem Assoc of Southwest VA, Inc - Wytheville
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Washington
Bellingham : Peace Health Medical Group
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Edmonds : Puget Sound Cancer Centers
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Edmonds : US Oncology - Puget Sound Cancer Center - Edmonds
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Everett : Providence Everett Medical Center
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Kennewick : Columbia Basin Hematology and Oncology
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
View More »
Seattle : Site Reference ID/Investigator# 52882
A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphoma
Seattle :
A Study of GA101 (RO5072759) in Combination With Chemotherapy in Patients With Previously Untreated Chronic Lymphocytic Leukemia (GALTON)
Seattle : US Oncology - Puget Sound Cancer Center - Seattle
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Seattle : University Of Washington
First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers
Seattle : Seattle Cancer Care Alliance
Study of BMN 673, a PARP Inhibitor, in Patients With Advanced Hematological Malignancies
Spokane : Medical Oncology Associates PS
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Spokane : US Oncology - Cancer Care Northwest - Holland
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Spokane : US Oncology - Cancer Care Northwest - Mission
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Spokane : US Oncology - Cancer Care Northwest - Sherman
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Spokane Valley : Cancer Care Northwest
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Tacoma :
A Study of GA101 (RO5072759) in Combination With Chemotherapy in Patients With Previously Untreated Chronic Lymphocytic Leukemia (GALTON)
Vancouver : US Oncology - Northwest Cancer Specialists, PC - Vancouver - 134th St
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Vancouver : US Oncology - Northwest Cancer Specialists, PC - Vancouver - 136th St.
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Walla Walla : Providence St. Mary Regional Cancer Center
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Yakima : Yakima Valley Memorial Hospital / North Star Lodge
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Yakima : US Oncology - Yakima Valley Memorial Hospital/North Star Lodge (Boyd)
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Yakima : North Star Lodge Cancer Center
Study to Investigate CAL-101 in Combination With Chemotherapeutic Agents and CD20 mAb in Patients With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia
Wisconsin
Green Bay : St. Vincent Hospital/Green Bay Oncology
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Green Bay : Bellin Memorial Hospital
Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL
Green Bay : St Vincent Regional Cancer Center
Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL
Janesville : Mercy Health System Heme/Onc
Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL
LaCrosse : Gundersen Clinic
Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL
View More »
Madison : Site Reference ID/Investigator# 56811
A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphoma
Madison : Investigational Site
A Study of the Safety and Pharmacokinetics of Escalating Doses of DCDT2980S in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia And DCDT2980S in Combination With Rituximab in Patients With Relapsed or Refractory B-Cell Non Hodgkin's Lymphoma
Madison : University of Wisconsin
An Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study
Madison : University of Wisconsin Carbone Cancer Center
Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL
Madison : University of Wisconsin
Study of BMN 673, a PARP Inhibitor, in Patients With Advanced Hematological Malignancies
Marshfield : Marshfield Clinic
Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL
Milwaukee : Medical College of Wisconsin
Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL
Oconomowoc : Oconomowoc Memorial Hospital
Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL
Waukesha : Waukesha Memorial Hospital
Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry
Waukesha : Waukesha Memorial Hospital
Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL
Wisconsin Rapids : Riverview Hospital
Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL
Australia
East Melbourne : Site Reference ID/Investigator# 48323
A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphoma
Parkville : Site Reference ID/Investigator# 48322
A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphoma
Austria
Feldkirch : LKH Feldkirch, Interne E
Rituximab Versus Observation as Maintenance Therapy in Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
Hall : A.ö. Bezirkskrankenhaus Hall in Tirol, Innere Medizin / Hämato - Onkologie
Rituximab Versus Observation as Maintenance Therapy in Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
Innsbruck : GSK Investigational Site Updated
Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia
Innsbruck : Universitätsklinik Innsbruck, Innere MEdizin IV / Hämato-Onkologie
Rituximab Versus Observation as Maintenance Therapy in Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
Krems : Landesklinikum Krems, Hämato-onkologisches Service
Rituximab Versus Observation as Maintenance Therapy in Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
View More »
Kufstein : A.ö. Bezirkskrankenhaus Kufstein, Innere Medizin / Hämatologie / Onkologie
Rituximab Versus Observation as Maintenance Therapy in Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
Linz : GSK Investigational Site Updated
Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia
Linz : AKH Linz, Department für Innere Medizin 3
Rituximab Versus Observation as Maintenance Therapy in Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
Salzburg : Universitätsklinik der PMU Salzburg, Univ-Klinik für Innere Medizin
Rituximab Versus Observation as Maintenance Therapy in Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
Steyr : Landeskrankenhaus Steyr, Innere Medizin, Hämatologie, Onkologie
Rituximab Versus Observation as Maintenance Therapy in Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
Wels : Klinikum Wels-Grieskirchen GmbH, Abteilung für Innere Medizin IV
Rituximab Versus Observation as Maintenance Therapy in Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
Wien : AKH Wien, Klinische Abteilung für Hämatologie und Hämostaseologie
Rituximab Versus Observation as Maintenance Therapy in Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
Wien : Hanusch Krankenhaus, 3. Med. Abtlg.
Rituximab Versus Observation as Maintenance Therapy in Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
Bulgaria
Sofia : GSK Investigational Site Updated
Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia
Canada
Brampton : CA009
Bendamustine Hydrochloride (HCl) in Indolent Non-Hodgkin's Lymphoma That Has Progressed During or Following Treatment With a Rituximab Regimen or Previously Untreated Chronic Lymphocytic Leukemia
Calgary : CA015
Bendamustine Hydrochloride (HCl) in Indolent Non-Hodgkin's Lymphoma That Has Progressed During or Following Treatment With a Rituximab Regimen or Previously Untreated Chronic Lymphocytic Leukemia
Edmonton : CA014
Bendamustine Hydrochloride (HCl) in Indolent Non-Hodgkin's Lymphoma That Has Progressed During or Following Treatment With a Rituximab Regimen or Previously Untreated Chronic Lymphocytic Leukemia
Halifax : CA004
Bendamustine Hydrochloride (HCl) in Indolent Non-Hodgkin's Lymphoma That Has Progressed During or Following Treatment With a Rituximab Regimen or Previously Untreated Chronic Lymphocytic Leukemia
Hamilton : CA003
Bendamustine Hydrochloride (HCl) in Indolent Non-Hodgkin's Lymphoma That Has Progressed During or Following Treatment With a Rituximab Regimen or Previously Untreated Chronic Lymphocytic Leukemia
View More »
Kelowna : CA016
Bendamustine Hydrochloride (HCl) in Indolent Non-Hodgkin's Lymphoma That Has Progressed During or Following Treatment With a Rituximab Regimen or Previously Untreated Chronic Lymphocytic Leukemia
Montreal : CA001
Bendamustine Hydrochloride (HCl) in Indolent Non-Hodgkin's Lymphoma That Has Progressed During or Following Treatment With a Rituximab Regimen or Previously Untreated Chronic Lymphocytic Leukemia
Montreal : CA010
Bendamustine Hydrochloride (HCl) in Indolent Non-Hodgkin's Lymphoma That Has Progressed During or Following Treatment With a Rituximab Regimen or Previously Untreated Chronic Lymphocytic Leukemia
Ottawa : CA002
Bendamustine Hydrochloride (HCl) in Indolent Non-Hodgkin's Lymphoma That Has Progressed During or Following Treatment With a Rituximab Regimen or Previously Untreated Chronic Lymphocytic Leukemia
Quebec : CA008
Bendamustine Hydrochloride (HCl) in Indolent Non-Hodgkin's Lymphoma That Has Progressed During or Following Treatment With a Rituximab Regimen or Previously Untreated Chronic Lymphocytic Leukemia
Toronto : CA006
Bendamustine Hydrochloride (HCl) in Indolent Non-Hodgkin's Lymphoma That Has Progressed During or Following Treatment With a Rituximab Regimen or Previously Untreated Chronic Lymphocytic Leukemia
Toronto : University Health Network - Princess Margaret Hospital
Open-Label Study of Lenalidomide in Combination With Oral Dexamethasone in the Treatment of Previously Untreated, Symptomatic Patients With Chronic Lymphocytic Leukemia
Vancouver : CA011
Bendamustine Hydrochloride (HCl) in Indolent Non-Hodgkin's Lymphoma That Has Progressed During or Following Treatment With a Rituximab Regimen or Previously Untreated Chronic Lymphocytic Leukemia
Victoria : CA013
Bendamustine Hydrochloride (HCl) in Indolent Non-Hodgkin's Lymphoma That Has Progressed During or Following Treatment With a Rituximab Regimen or Previously Untreated Chronic Lymphocytic Leukemia
Windsor : CA005
Bendamustine Hydrochloride (HCl) in Indolent Non-Hodgkin's Lymphoma That Has Progressed During or Following Treatment With a Rituximab Regimen or Previously Untreated Chronic Lymphocytic Leukemia
Czech Republic
Brno : FN Brno
Rituximab Versus Observation as Maintenance Therapy in Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
Hradec Kralove : FN Hradec Kralove
Rituximab Versus Observation as Maintenance Therapy in Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
Olomouc : FN Olomouc
Rituximab Versus Observation as Maintenance Therapy in Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
Praha : VFN Praha 2
Rituximab Versus Observation as Maintenance Therapy in Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
Praha : FN Kralovske Vinohrady
Rituximab Versus Observation as Maintenance Therapy in Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
France
Lille cedex : GSK Investigational Site Updated
Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia
Germany
Dresden : GSK Investigational Site Updated
Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia
Koblenz : GSK Investigational Site Updated
Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia
Regensburg : GSK Investigational Site Updated
Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia
Hungary
Budapest : GSK Investigational Site Updated
Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia
Debrecen : GSK Investigational Site Updated
Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia
Israel
Jerusalem : GSK Investigational Site Updated
Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia
Rehovot : Kaplan Medical Center
The Humanized Monoclonal Antibody Milatuzumab for Refractory Chronic Lymphocytic Leukemia (CLL)
Italy
Brescia : GSK Investigational Site Updated
Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia
Genova : University Hospital San Martino
NOX-A12 in Combination With Bendamustine and Rituximab in Relapsed Chronic Lymphocytic Leukemia (CLL)
Milano : GSK Investigational Site Updated
Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia
Poland
Chorzow : GSK Investigational Site Updated
Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia
Wroclaw : GSK Investigational Site Updated
Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia
Russian Federation
Chelyabinsk : GSK Investigational Site Updated
Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia
Moscow : GSK Investigational Site Updated
Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia
St. Petersburg : GSK Investigational Site Updated
Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia
St'Petersburg : GSK Investigational Site Updated
Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia
Singapore
Singapore : GSK Investigational Site Updated
Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia
Slovakia
Bansky Bystrica : F.D. Rossevelt hospital
Rituximab Versus Observation as Maintenance Therapy in Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
Bratislava : GSK Investigational Site Updated
Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia
Bratislava : FNsP sv. Cyrila a Metoda
Rituximab Versus Observation as Maintenance Therapy in Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
Bratislava : Narodny onkologicky ustav
Rituximab Versus Observation as Maintenance Therapy in Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
Kosice : FNsP L.Pasteura
Rituximab Versus Observation as Maintenance Therapy in Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
View More »
Martin : Martinska fakultna nemocnica
Rituximab Versus Observation as Maintenance Therapy in Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
Presov : FNsP J.A. Reimana
Rituximab Versus Observation as Maintenance Therapy in Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
Spain
Badalona : Hospital Germans Trias i Pujol
Ofatumumab as Part of Reduced Intensity Conditioning (RIC) Regimen for Patients With High Risk Chronic Lymphocytic Leukemia (CLL) Undergoing Allogeneic Hematopoietic Cell Transplantation
Barcelona : Hospital de la Santa Creu Sant Pau
Ofatumumab as Part of Reduced Intensity Conditioning (RIC) Regimen for Patients With High Risk Chronic Lymphocytic Leukemia (CLL) Undergoing Allogeneic Hematopoietic Cell Transplantation
Barcelona : Hospital Vall d'Hebron
Ofatumumab as Part of Reduced Intensity Conditioning (RIC) Regimen for Patients With High Risk Chronic Lymphocytic Leukemia (CLL) Undergoing Allogeneic Hematopoietic Cell Transplantation
Córdoba : Hospital Universitario Reina Sofía
Activity & Safety Study of Lenalidomide & Rituximab as Non-chemotherapy Based Therapy on Chronic Lymphocytic Leukemia
Córdoba : Hospital Universitario Reina Sofía
Activity and Safety of Lenalidomide and Rituximab (LenRtx) as Non-chemotherapy Based Therapy for Patients With Chronic Lymphocytic Leukemia
View More »
Hospitalet de Llobregat : Institut Catala d'Oncologia
Ofatumumab as Part of Reduced Intensity Conditioning (RIC) Regimen for Patients With High Risk Chronic Lymphocytic Leukemia (CLL) Undergoing Allogeneic Hematopoietic Cell Transplantation
Madrid : Fundación MD Anderson Internacional
Activity & Safety Study of Lenalidomide & Rituximab as Non-chemotherapy Based Therapy on Chronic Lymphocytic Leukemia
Madrid : Hospital Universitario La Paz
Activity & Safety Study of Lenalidomide & Rituximab as Non-chemotherapy Based Therapy on Chronic Lymphocytic Leukemia
Madrid : Fundación MD Anderson Internacional
Activity and Safety of Lenalidomide and Rituximab (LenRtx) as Non-chemotherapy Based Therapy for Patients With Chronic Lymphocytic Leukemia
Madrid : Hospital Universitario La Paz
Activity and Safety of Lenalidomide and Rituximab (LenRtx) as Non-chemotherapy Based Therapy for Patients With Chronic Lymphocytic Leukemia
Madrid : Hospital La Princesa
Ofatumumab as Part of Reduced Intensity Conditioning (RIC) Regimen for Patients With High Risk Chronic Lymphocytic Leukemia (CLL) Undergoing Allogeneic Hematopoietic Cell Transplantation
Madrid : Hospital Puerta de Hierro
Ofatumumab as Part of Reduced Intensity Conditioning (RIC) Regimen for Patients With High Risk Chronic Lymphocytic Leukemia (CLL) Undergoing Allogeneic Hematopoietic Cell Transplantation
Oviedo : Hospital Central de Asturias
Ofatumumab as Part of Reduced Intensity Conditioning (RIC) Regimen for Patients With High Risk Chronic Lymphocytic Leukemia (CLL) Undergoing Allogeneic Hematopoietic Cell Transplantation
Salamanca : Hospital Clínico de Salamanca
Activity & Safety Study of Lenalidomide & Rituximab as Non-chemotherapy Based Therapy on Chronic Lymphocytic Leukemia
Salamanca : Hospital Clínico de Salamanca
Activity and Safety of Lenalidomide and Rituximab (LenRtx) as Non-chemotherapy Based Therapy for Patients With Chronic Lymphocytic Leukemia
Sevilla : Hospital Virgen del Rocío
Activity and Safety of Lenalidomide and Rituximab (LenRtx) as Non-chemotherapy Based Therapy for Patients With Chronic Lymphocytic Leukemia
Valencia : Hospital Clínico Universitario de Valencia
Activity & Safety Study of Lenalidomide & Rituximab as Non-chemotherapy Based Therapy on Chronic Lymphocytic Leukemia
Valencia : Hospital Clínico Universitario de Valencia
Activity and Safety of Lenalidomide and Rituximab (LenRtx) as Non-chemotherapy Based Therapy for Patients With Chronic Lymphocytic Leukemia
Valencia : Hospital Clinico
Ofatumumab as Part of Reduced Intensity Conditioning (RIC) Regimen for Patients With High Risk Chronic Lymphocytic Leukemia (CLL) Undergoing Allogeneic Hematopoietic Cell Transplantation
Valencia : Hospital La Fe
Ofatumumab as Part of Reduced Intensity Conditioning (RIC) Regimen for Patients With High Risk Chronic Lymphocytic Leukemia (CLL) Undergoing Allogeneic Hematopoietic Cell Transplantation
Zaragoza : Hospital Universitario Miguel Servet
Activity & Safety Study of Lenalidomide & Rituximab as Non-chemotherapy Based Therapy on Chronic Lymphocytic Leukemia
Zaragoza : Hospital Universitario Miguel Servet
Activity and Safety of Lenalidomide and Rituximab (LenRtx) as Non-chemotherapy Based Therapy for Patients With Chronic Lymphocytic Leukemia
Sweden
Göteborg : GSK Investigational Site Updated
Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia
Stockholm : GSK Investigational Site Updated
Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia
Uppsala : GSK Investigational Site Updated
Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia
Ukraine
Cherkasy : GSK Investigational Site Updated
Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia
Dnipropetrovsk : GSK Investigational Site Updated
Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia
Kharkiv : GSK Investigational Site Updated
Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia
Kyiv : GSK Investigational Site Updated
Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia
Lviv : GSK Investigational Site Updated
Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia
View More »
Makiivka : GSK Investigational Site Updated
Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia
Vinnitsa : GSK Investigational Site Updated
Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia
United Kingdom
London : King's College Hospital
Study of BMN 673, a PARP Inhibitor, in Patients With Advanced Hematological Malignancies
London : University College London
Study of BMN 673, a PARP Inhibitor, in Patients With Advanced Hematological Malignancies
Manchester : The Christie NHS Foundation
Study of BMN 673, a PARP Inhibitor, in Patients With Advanced Hematological Malignancies
Newcastle upon Tyne : University of Newcastle Upon Tyne, NHS Foundation Trust
Study of BMN 673, a PARP Inhibitor, in Patients With Advanced Hematological Malignancies
Oxford : GSK Investigational Site Updated
Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia
United States
Washington : Investigational Site
A Study of the Safety and Pharmacokinetics of Escalating Doses of DCDT2980S in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia And DCDT2980S in Combination With Rituximab in Patients With Relapsed or Refractory B-Cell Non Hodgkin's Lymphoma
Washington : Georgetown University
Ofatumumab and Bendamustine for Previously Treated Chronic Lymphocytic Leukemia (CLL)
Washington : Georgetown University Hospital/Lombardi Cancer Center
Trial of Bendamustine, Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL)
